Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aviptadil - Relief Therapeutics Holdings

Drug Profile

Aviptadil - Relief Therapeutics Holdings

Alternative Names: aviptadil acetate; DasKloster 1000; DasKloster 1000-01; DasKloster 1000-02; DasKloster 1000-03; DasKloster 1000-04; DK-1000; RLF-100; RLF-100 IV; RLF-100TM; SamiAIR™; SamiVIP™; SAMIVIR™; Vasoactive intestinal peptide; Vasoactive intestinal peptide hybrid; VIP; ZYESAMI

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mondoBIOTECH
  • Developer Centurion Pharma; Lung Rx; mondoBIOTECH; NRx Pharmaceuticals; Quantum Leap Healthcare Collaborative; RELIEF THERAPEUTICS Holding; University of Freiburg
  • Class Anti-inflammatories; Antifibrotics; Antivirals; Gastrointestinal hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action Vasoactive intestinal peptide replacements; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Acute lung injury; Pulmonary sarcoidosis; Idiopathic pulmonary fibrosis; Adult respiratory distress syndrome; Pulmonary arterial hypertension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered SARS-CoV-2 acute respiratory disease
  • Phase III Pulmonary sarcoidosis
  • Phase II COVID 2019 infections
  • Discontinued Adult respiratory distress syndrome; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 18 Jan 2024 Cantonal Hosptal, Baselland terminates a phase II trial for COVID-2019 infections in Switzerland due to difficulties recruiting participants as there are very few hospitalized COVID patients and even after continuous screening none of the patients met the eligibility criteria (Inhalation) (NCT04536350)
  • 19 May 2023 Updated efficacy data from the phase IIb/III COVID-AIV trial in SARS-COV-2 acute respiratory disease presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 03 Feb 2023 NeuroRx terminates the AVICOVID-2 phase IIb/III trial in SARS-COV-2 acute respiratory disease (In children, In adults, In adolescents, In the elderly) in USA (Inhalation) due to sponsor's decision (NCT04360096)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top